1. Contact Us
  2. Sitemap
 
Contact Us
Aventis House

54/A, Sir Mathuradas Vasanji Road,
Andheri (E),
Mumbai 400 093
India 

Board Tel:(91-22)28278000
Fax: (91-22) 28370939


For redressal of investor 
grievances, please write to
or contact Mr. K. Subramani,
Company Secretary  & 
Compliance Officer.
 


E Mail ID :

igrc.apl@sanofi-aventis.com 

Tel. Nos. (91-22)  28278530
                          28242260
Fax No.    (91-22) 28360862


 

Contact us

A world-class pharmaceutical manufacturer
Print
Aventis Pharma Limited was incorporated in May 1956 under the name Hoechst Fedco Pharma Private Limited. Over the years, its name was changed to Hoechst Pharmaceuticals Private Limited, Hoechst India Limited and Hoechst Marion Roussel Limited.

Sanofi-aventis, one of the world's leading pharmaceutical companies, and its 100% subsidiary, Hoechst GmbH, are the major shareholders of Aventis Pharma Limited and together hold 50.12% of its paid-up share capital.
 
The shares of Aventis Pharma Limited are quoted on the Bombay Stock Exchange (Security Code: 500674) and the National Stock Exchange (Security Code: AVENTIS EQ).


Shareholding Pattern (as on 30th Jun 2010)
  N° of
shareholders
N° of
shares held
% of
shares held
a) Foreign Promoters
(Hoechst GmbH/ Sanofi-aventis)
213,909,58760.40
b) Mutual Funds / UTI273,348,79714.54
c) Foreign Institutional Investors222,085,7109.06
d) Banks121,3950.01
e) Insurance Companies4959,1264.16
f) Bodies Corporate2901,206,3545.24
g) Trusts53900.002
h) Clearing Members674,7930.02
i)Individuals holding upto Rs.1 lakh in nominal capital14,2821,248,3805.42
j)Individuals holding more than Rs.1 lakh in nominal capital357,4900.25
k)Non-Resident Indians (Repatriable)12412,0110.05
l)Non-Resident Indians (non Repatriable)85196,5890.85
TOTAL14,92323,030,622100


  July 19, 2010

Corporate Information
Get more information about sanofi-aventis group
Read more

Medical Information / Pharmacovigilance

A key activity of sanofi-aventis is to provide updated medical information on its products, to healthcare professionals, which is in compliance with Indian regulations. All consumers or patients are advised to contact their doctor or healthcare professional for advice on medicines or any health matters.

For medical information, contact:
medinfo.india@sanofi-aventis.com

Sanofi-aventis also ensures continuous monitoring and management of the safety profile of all its products through its drug safety data collection worldwide, as pharmacovigilance remains a key activity in the assessment of the therapeutic value of products.

For information on Drug Safety and Reporting of Adverse Events, please contact:

Dr. Rajani Rokade, Affiliate Pharmacovigilance Head
Tel.: +91-22-28278055
Fax: +91-22-28208667 /
       +91-22-28278044
Email:
pv.india@sanofi-aventis.com


  1. Copyright © 2006-2010 sanofi-aventis. All rights reserved. Legal Notice